Verastem has given shareholders a rough ride over the longer term, yet the share price has moved sharply enough at times to keep the story alive. With that backdrop, the live question is whether today's valuation can be squared with what the business is generating in sales.
-
The stock is down 70.7% over 5 years. This puts the focus squarely on whether the current share price is now leaning too heavily on future sales potential rather than what is already in place.
-
The company is still in a phase where commercialisation, funding needs and execution on its drug pipeline may shape how much investors are willing to pay for each dollar of revenue.
-
Your read on Verastem is one view; the desks covering it have another. See what analysts think Verastem's shares could be worth .
The issue now is whether the price investors are paying for Verastem today can be justified by its sales alone.
If you want to test the same sales based valuation question that hangs over Verastem against a wider field, start with 30 high quality undervalued stocks .
Does Verastem Look Fairly Valued on Sales?
P/S makes more sense for Verastem because investors are mainly weighing its revenue potential rather than current profits. On this yardstick, the stock trades on a P/S of 13.4x, which is slightly higher than the Biotechs sector average of 11.9x and also above the peer group on 12.9x. That indicates the market is already paying a small premium for each dollar of Verastem's sales compared with similar drug developers.
The fair multiple suggested by the valuation model is a tailored figure that reflects Verastem's growth profile, profitability prospects, scale and risk. The current 13.4x P/S sits close to that reference point, which suggests the share price is roughly in line with what this framework would expect for the business. If you are weighing an entry or exit, the key consideration is whether your own view of Verastem's future sales and execution risk is more cautious or more optimistic than what this near fair P/S level implies for the years ahead. Explore the numbers behind Verastem's P/S valuation .
The Verastem Narrative: What Would Justify Today's Price?
Narratives pick up where the Verastem valuation question leaves off by spelling out what sort of future for growth, margins and earnings would need to unfold for the stock to be worth significantly more or materially less than it is today. Each scenario ties a fair value estimate to a specific mix of potential catalysts and risks so you can watch over time which version of Verastem's story is actually taking shape on Simply Wall St's Community page.
One of the top community narratives on Verastem: 19% undervalued
"The main thing that has to go right is that VS-7375 progresses from the current Phase 2 and planned Phase 3 programs in pancreatic, colorectal and non small cell lung cancer…"
Discover why this Narrative puts Verastem at 19% undervalued .
One more angle on Verastem that could change the story
Price tags and pipelines only go so far, because the real question is who is steering Verastem and how their pay packets line up with your interests. See who runs Verastem and how they are paid .
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include VSTM .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
